このエントリーをはてなブックマークに追加
ID 55327
FullText URL
Author
Igawa, Takuro Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sato, Yasuharu Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takata, Katsuyoshi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwaki, Noriko Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tanaka, Takehiro Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Asano, Naoko Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Maeda, Yoshinobu Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Orita, Yorihisa Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nakamura, Naoya Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nakamura, Shigeo Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshino, Tadashi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
 D cyclins positively regulate the cell cycle and mediate the pathogenesis of some lymphomas. Cyclin D1 overexpression is the hallmark of mantle cell lymphoma, whereas cyclins D2 and D3 are reportedly not as specific to certain lymphomas as cyclin D1. In this study, cyclin D2 was found to be overexpressed in 98% of de novo CD5-positive diffuse large B-cell lymphomas (DLBCLs) (50/51) and in 28% of CD5-negative DLBCLs (14/51). A statistically significant difference was observed between these two groups (p<0.0001). In contrast, no statistical difference was found in the cyclin D3 expression between CD5-positive (18/51) and CD5-negative (24/51) DLBCLs (p=0.23). Based on these findings, cyclin D2 is therefore considered to be closely associated with de novo CD5-positive DLBCLs. This insight may be useful for overcoming the inferior survival of this aggressive lymphoma.
Keywords
Cyclin D2
CD5
Diffuse large B-cell lymphoma
Note
学位審査副論文
Published Date
2013-05-15
Publication Title
Diagnostic Pathology
Volume
volume8
Publisher
BioMed Central
Start Page
81
ISSN
1746-1596
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version
publisher
PubMed ID
DOI
Web of Sience KeyUT
Related Url
https://doi.org/10.1186/1746-1596-8-81
http://ousar.lib.okayama-u.ac.jp/54287